Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus Clinical research trials and Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus. Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus clinical trial. Subjects frequently obtain the most expert healthcare possible for their Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "P" Clinical Trials Conditions > Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus



Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

For Condition: Pemphigus
Status: No longer recruiting
Sponsor(s): Johns Hopkins Oncology Center ,
Synopsis: OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
Details: PROTOCOL OUTLINE: Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover. Patients are followed monthly for 6 months, every 2 months for 6 months, every 4 months for a year, and then annually thereafter.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/70 Years
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Definitive diagnosis of pemphigus, including all of the following: Typical clinical lesions Histologically proven by skin or mucous membrane biopsy Pemphigus IgG autoantibodies in skin or mucous membrane by direct immunofluorescence (IF) Circulating pemphigus IgG autoantibodies in serum by indirect IF Dependence on high-dose corticosteroids Persistent disease activity despite treatment with mycophenolate mofetil or azathioprine, or inability to tolerate these drugs (for paraneoplastic pemphigus, persistent disease activity despite treatment with cyclosporine) --Prior/Concurrent Therapy-- No concurrent cytotoxic therapy --Patient Characteristics-- Performance status: Karnofsky 20-100% Renal: Creatinine no greater than 2.5 mg/dL Cardiovascular: LVEF at least 40% Pulmonary: FVC, FEV1, or DLCO at least 50% predicted Other: Not pregnant Fertile patients must use effective contraception during and for 9 months after study Not preterminal or moribund
Total Enrollment: 35

Location and Contact Information:

Overall Study Official:
GrantAnhalt,  Study Chair,  Johns Hopkins Oncology Center

Johns Hopkins University School of Medicine
Baltimore,  Maryland,  21205
United States
 


Additional Information:
Study ID Numbers:  199/15674;  JHOC-99022610,JHOC-J9912
Study Start Date: April 1999
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00010413

Other Pemphigus Studies:
1. Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

Related Studies:

Other Pemphigus Clinical Trials
Other Maryland Clinical Trials
Other Baltimore Clinical Trials

Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
Modify your Search

  Other Pemphigus Clinical Trials
  Other Maryland Clinical Trials
  Other Baltimore Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103